All Insights

Rare earths aren't actually rare — deposits exist on every continent. What's concentrated is processing, a capability built over decades. Here's how the mining-to-magnets supply chain works, where global diversification efforts stand, and how investors can gain exposure to both the established leader and the emerging alternatives.

What actually happens inside a pharma company before a $10 billion acquisition gets announced? This piece maps the real decision framework — build vs. partner vs. buy, the screening checklist, and why a target's leverage is easy to underestimate — using real negotiations like Novartis's standoff with Avidity Biosciences.

A $300 billion patent cliff is reshaping how Big Pharma buys. This piece maps five years of deal data to show why two-thirds of acquisitions are still bets on unproven science, how J&J's incubator network actually pays off, and what separates a slow "partner-first" deal like Roche/Genentech from a cold, competitive bidding war like GSK/Nuvalent.

Gas prices are elevated because of a war-driven risk premium, not a physical shortage — Iran-linked disruptions and Ukraine's campaign against Russian refineries are both squeezing supply. A permanent decline requires both conflicts to reach a resolution that actually holds, not just a pause, and neither is currently in view.

Getting acquired well isn't luck — it's the result of decisions made years earlier. Using SEC filings from Seagen, Avidity Biosciences, and Verona Pharma, this piece walks through exactly how founders identify the right buyer, price their asset, and negotiate from strength instead of desperation.

Four widely held assets — VGT, VOO, VONG, and gold — moved in noticeably different directions over the same two-week window in July 2026, despite facing overlapping macro pressures. The divergence isn't random: it traces directly to how concentrated each fund's exposure is to the forces currently in play, from an AI-chip valuation reset to a shifting Fed rate outlook. This piece breaks down why sector concentration, not headline risk, is driving the split.

AI in pharma is often described as one trend. It's really two, and it only wins one on its own merits. In drug discovery, AI directly attacks the problem of finding the right molecule, letting small teams compete with giants using nothing but data and talent. In drug manufacturing, AI can't shortcut anything, since it depends on years of proprietary production data that only exists once a company has already built an expensive facility, for reasons that have nothing to do wit

From a chemically synthesized pill to a patient's own genetically engineered living cells, drug modalities span an enormous range of manufacturing difficulty. This article explains why the pharmaceutical industry needs so many different approaches in the first place, then ranks every major modality, from small molecules to gene therapy, by how hard it actually is to build, and why.

Antibody-drug conjugates are among the most complex drugs ever built, combining an antibody, a chemical linker, and a toxic payload into a single guided-missile therapy for cancer. That complexity hasn't stopped pharmaceutical giants from spending tens of billions of dollars chasing the technology. This article breaks down why ADCs are so hard to manufacture, why Japan's Daiichi Sankyo has built the strongest platform in the field, and how a newly approved bispecific ADC out

Seven real founders, seven different ways to fund an asset management firm. Here's what they have in common — and what each pathway actually requires of the person attempting it.